Substituted indole Mcl-1 inhibitors
US12144816B2 · kind B2 · utility
0Cited by
8References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 9, 2022 |
| Grant date | Nov 19, 2024 |
| Priority date | — |
| Expiry date | Feb 5, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present disclosure also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.